All News

Found 2,625 articles

• Abeona Therapeutics Doses First Patient In Phase 1/2 Trial With ABO-102 Gene Therapy For Patients With Sanfilippo Syndrome Type A (MPS IIIA)

  5/18/2016

• Bayer And ERS Genomics Announce Licensing Agreement For Genome Editing Patents

  5/17/2016

• Agenovir Completes $10.6 Million Series A Financing

  5/17/2016

• Bay Area's Caribou Biosciences Reels in $30 Million

  5/16/2016

• A Look at 4 People Molding Kendall Square's Future

  5/9/2016

• Juniper Pharma Announces Publication Of Phase 1 Study Demonstrating Ability Of Its Proprietary Intravaginal Ring To Deliver Large Molecules

  5/5/2016

• Regeneron Reports First Quarter 2016 Financial And Operating Results

  5/5/2016

• 3 Stocks with Moonshot Potential that are Safer Buys than bluebird bio

  5/4/2016

• Bio-Techne Acquires Access To B-MoGen Biotechnologies' Gene Editing Technology

  5/4/2016

• The Pershing Square Sohn Cancer Research Alliance Awards Funding To Seven New York City-Based Cancer Research Scientists

  5/4/2016

• Thomson Reuters Unveils Nominees For The Top BioPharma Deals Of The Year

  5/3/2016

• Startup Homology Medicines Launches With $43 Million Series A, To Be Led By Three Former Shire Execs

  5/2/2016

• MaxCyte, Inc. To Present Gene Editing Results At The American Society Of Gene And Cell Therapy Annual Meeting

  4/21/2016

• Bay States's Intellia Discloses a $125 Million CRISPR/Cas Deal with Regeneron and Files for $120 Million IPO

  4/12/2016

• Cellecta, Inc. SBIR Grant Work Finds Way To Increase CRISPR Effectiveness For Genetic Screens

  4/12/2016

• Cellecta, Inc. SBIR Grant Work Finds Way To Increase CRISPR Effectiveness For Genetic Screens

  4/12/2016

• Top 5 Biotech Winners and Losers of Q1 2016

  4/1/2016

• Caribou Biosciences' Co-Founder Dr. Jennifer Doudna And Chairman Of The Board Rodolphe Barrangou Selected For 2016 Canada Gairdner Awards

  3/24/2016

• 2016 Canada Gairdner Awards Honour CRISPR-Cas Researchers And HIV/AIDS Leaders

  3/23/2016

• Excision BioTherapeutics Release: Use Of CRISPR Cas9 Gene Editing Therapeutic Shown To Permanently Inactivate HIV-1 In Patient's Blood For First Time

  3/22/2016